To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Speech in Other Business - Wed 27 Mar 2024
Arbitration Bill [HL]

Speech Link

View all Lord Mendelsohn (Lab - Life peer) contributions to the debate on: Arbitration Bill [HL]

Speech in Other Business - Wed 27 Mar 2024
Arbitration Bill [HL]

Speech Link

View all Lord Mendelsohn (Lab - Life peer) contributions to the debate on: Arbitration Bill [HL]

Speech in Other Business - Wed 27 Mar 2024
Arbitration Bill [HL]

Speech Link

View all Lord Mendelsohn (Lab - Life peer) contributions to the debate on: Arbitration Bill [HL]

Written Question
Evusheld
Friday 22nd March 2024

Asked by: Lord Mendelsohn (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether the COVID-19 monoclonal antibody Evusheld 2.0 is being treated as a priority for assessment; and whether they have any plans to rollout a programme to be fast-tracked to vulnerable patients.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

AZD-3152, which has been referred to as Evusheld 2.0, will be evaluated through the National Institute for Health and Care Excellence’s (NICE) standard appraisal process. The NICE is the independent body responsible for developing evidence-based guidance on whether new medicines should be routinely funded by the National Health Service, based on an assessment of their costs and benefits.

The NICE has formally started its appraisal of AZD-3152, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible.

If AZD-3152 is recommended as clinically and cost effective by the NICE, the NHS in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations. There are no plans for the NHS to routinely fund the medicine ahead of it achieving a licence or a positive technology appraisal recommendation from the NICE.


Division Vote (Lords)
11 Mar 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Lord Mendelsohn (Lab) voted Aye - in line with the party majority and in line with the House
One of 106 Labour Aye votes vs 1 Labour No votes
Vote Tally: Ayes - 209 Noes - 193
Division Vote (Lords)
11 Mar 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Lord Mendelsohn (Lab) voted Aye - in line with the party majority and in line with the House
One of 105 Labour Aye votes vs 1 Labour No votes
Vote Tally: Ayes - 204 Noes - 192
Division Vote (Lords)
11 Mar 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Lord Mendelsohn (Lab) voted Aye - in line with the party majority and against the House
One of 106 Labour Aye votes vs 1 Labour No votes
Vote Tally: Ayes - 199 Noes - 199
Division Vote (Lords)
11 Mar 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Lord Mendelsohn (Lab) voted Aye - in line with the party majority and in line with the House
One of 105 Labour Aye votes vs 1 Labour No votes
Vote Tally: Ayes - 217 Noes - 192
Division Vote (Lords)
11 Mar 2024 - Digital Markets, Competition and Consumers Bill - View Vote Context
Lord Mendelsohn (Lab) voted Aye - in line with the party majority and in line with the House
One of 105 Labour Aye votes vs 1 Labour No votes
Vote Tally: Ayes - 202 Noes - 187
Division Vote (Lords)
6 Mar 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Lord Mendelsohn (Lab) voted Aye - in line with the party majority and in line with the House
One of 121 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 228 Noes - 184